Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Avory & Company LLC

Avory & Company LLC lowered its position in Omnicell, Inc. (NASDAQ:OMCL) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 241,206 shares of the company’s stock after selling 12,926 shares during the period. Omnicell comprises approximately 6.0% of Avory & Company LLC’s holdings, making the stock its 6th largest position. Avory & Company LLC owned about 0.52% of Omnicell worth $10,738,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in OMCL. Smartleaf Asset Management LLC lifted its position in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the period. Van ECK Associates Corp increased its holdings in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares in the last quarter. KBC Group NV increased its holdings in Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after buying an additional 778 shares in the last quarter. Finally, CIBC Asset Management Inc purchased a new position in Omnicell in the fourth quarter valued at about $201,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Wells Fargo & Company dropped their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Bank of America dropped their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Benchmark reissued a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell currently has an average rating of “Hold” and an average price target of $52.33.

Omnicell Trading Up 1.2 %

Shares of OMCL opened at $37.82 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm has a 50 day simple moving average of $42.03 and a 200-day simple moving average of $43.72. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.75. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of 140.08, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.64% of the stock is owned by corporate insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.